Investment Thesis
Vivos faces critical financial distress with negative stockholders' equity (-$1.5M), unsustainable cash burn (-$17.6M FCF annually), and only $2M cash remaining—implying ~5 weeks of operational runway. Despite 16% revenue growth and healthy 60.4% gross margins, massive operating losses (-$19.9M) and technical insolvency create extreme downside risk requiring immediate capital infusion or restructuring.
Strengths
- Revenue growth of 16% YoY demonstrates market demand for surgical products
- Gross margin of 60.4% shows healthy pricing power and cost structure typical of medical devices
- Surgical instruments sector offers recurring revenue potential if financial viability is restored
Risks
- Negative stockholders' equity of -$1.5M indicates technical insolvency and balance sheet deterioration
- Critical liquidity crisis: current ratio of 0.24x with only $2M cash against -$15.3M operating cash burn
- Operating losses of -$19.9M exceed revenue of $17.4M—business model fundamentally unprofitable at current scale
- Going concern risk with estimated 5-7 weeks of cash runway at current burn rates without capital raise
Key Metrics to Watch
- Cash runway and monthly burn rate trajectory
- Capital raise announcements or debt restructuring
- Path to operating profitability and gross margin stability
Financial Metrics
Revenue
17.4M
Net Income
-21.2M
EPS (Diluted)
$-2.07
Free Cash Flow
-17.6M
Total Assets
25.2M
Cash
2.0M
Profitability Ratios
Gross Margin
60.4%
Operating Margin
-114.1%
Net Margin
-121.4%
ROE
N/A
ROA
-84.2%
FCF Margin
-100.9%
Balance Sheet & Liquidity
Current Ratio
0.24x
Quick Ratio
0.24x
Debt/Equity
N/A
Debt/Assets
106.2%
Interest Coverage
-14.21x
Long-term Debt
753.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T22:54:22.391546 |
Data as of: 2025-12-31 |
Powered by Claude AI